Fas and the TRAIL receptors, DR4 and DR5, are apoptosis-inducing members of the Tumor Necrosis Factor Receptor (TNFR) family that play a key role in the regulation of immune response. In addition to their known role in the mediation of apoptosis, these receptors are also known to activate the NF-kappaB and JNK pathways. However, the signaling events involved in the activation of these pathways by the Fas and TRAIL receptors have not been characterized. We have discovered that caspase 8 and its homologs, caspase 10 and MRIT, are likely to play a major role in NF-kappaB and JNK activation via Fas and DR4/DR5. These properties of caspase 8 may also explain the recently discovered role of the FADD-caspase 8 pathway in T cell activation and proliferation. The overall objective of this proposal is to further characterize the role of caspase 8 and its homologs in NF-kappaB and JNK activation by Fas and DR4/DR5 and study its biological significance. This objective will be achieved through the following specific aims.
In specific aim 1, cell lines deficient in caspase 8, or expressing its mutant constructs, will be used to confirm its role in NF-kappaB and JNK activation by Fas and DR4/DR5.
In specific aim 2, the molecular interactions underlying the NF-kappaB and JNK activating abilities of caspase 8 and homologs will be characterized and any novel protein(s) involved in these processes identified.
In specific aim 3, role of caspase 8- and its homologs-mediated NF-kappaB and JNK activation in the process of T cell activation and development will be studied by in vitro studies in cell lines and in vivo studies in transgenic animals. We hope that the above studies will not only clarify the role of caspase 8 and its homologs in NF-kappaB and JNK activation by the Fas and TRAIL receptors but also enhance our understanding of the molecular interactions involved in immune regulation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI047230-05
Application #
6721548
Study Section
Immunobiology Study Section (IMB)
Program Officer
Winter, David B
Project Start
2000-04-01
Project End
2004-08-31
Budget Start
2004-04-01
Budget End
2004-08-31
Support Year
5
Fiscal Year
2004
Total Cost
$85,652
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Chugh, Priti; Matta, Hittu; Schamus, Sandra et al. (2005) Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc Natl Acad Sci U S A 102:12885-90
Rathore, Nisha; Matta, Hittu; Chaudhary, Preet M (2004) An evolutionary conserved pathway of nuclear factor-kappaB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IkappaBalpha. J Biol Chem 279:39358-65
Shivapurkar, Narayan; Toyooka, Shinichi; Toyooka, Kiyomi O et al. (2004) Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109:786-92
Shivapurkar, Narayan; Reddy, Jyotsna; Chaudhary, Preet M et al. (2003) Apoptosis and lung cancer: a review. J Cell Biochem 88:885-98
Shivapurkar, Narayan; Reddy, Jyotsna; Matta, Hittu et al. (2002) Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21:8510-4
Shivapurkar, Narayan; Toyooka, Shinichi; Eby, Michael T et al. (2002) Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 1:65-9
Harada, Kenichi; Toyooka, Shinichi; Shivapurkar, Narayan et al. (2002) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62:5897-901
Taylor, M A; Chaudhary, P M; Klem, J et al. (2001) Inhibition of the death receptor pathway by cFLIP confers partial engraftment of MHC class I-deficient stem cells and reduces tumor clearance in perforin-deficient mice. J Immunol 167:4230-7